Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meral Beksac

Showing results (61-70 of 185) with videos related to

Pageof 19
Sort By:
Haematologica|June 1, 2005
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trialNorbert Schmitz, Meral Beksac, Andrea Bacigalupo, et al.
The Lancet. Haematology|September 29, 2022
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paperNico Gagelmann, Anna Sureda, Silvia Montoto, et al.
Blood|June 28, 2003
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowNorbert C Gorin, Myriam Labopin, Vanderson Rocha, et al.
Journal of Clinical Medicine|September 10, 2021
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study GroupJelena Bila, Eirini Katodritou, Margarita Guenova, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Leukemia Research|August 3, 2010
Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trialMeral Beksac, Ridvan Ali, Tulay Ozcelik, et al.
European Journal of Haematology|October 15, 2010
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study GroupMeral Beksac, Rauf Haznedar, Tulin Firatli-Tuglular, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
British Journal of Haematology|December 20, 2023
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance casesErman Akkus, Timur Tuncalı, Hasan Yalım Akın, et al.
Current Research in Translational Medicine|March 6, 2024
In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamideEmine Begum Gencer, Hasan Yalim Akin, Selami Kocak Toprak, et al.
Pageof 19

Showing results (61-70 of 185) with videos related to

Sort By:
Pageof 19
Haematologica|June 1, 2005
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trialNorbert Schmitz, Meral Beksac, Andrea Bacigalupo, et al.
The Lancet. Haematology|September 29, 2022
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paperNico Gagelmann, Anna Sureda, Silvia Montoto, et al.
Blood|June 28, 2003
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowNorbert C Gorin, Myriam Labopin, Vanderson Rocha, et al.
Journal of Clinical Medicine|September 10, 2021
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study GroupJelena Bila, Eirini Katodritou, Margarita Guenova, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Leukemia Research|August 3, 2010
Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: results of a randomized multicenter phase III trialMeral Beksac, Ridvan Ali, Tulay Ozcelik, et al.
European Journal of Haematology|October 15, 2010
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study GroupMeral Beksac, Rauf Haznedar, Tulin Firatli-Tuglular, et al.
Haematologica|March 20, 2025
Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trialSalomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
British Journal of Haematology|December 20, 2023
Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance casesErman Akkus, Timur Tuncalı, Hasan Yalım Akın, et al.
Current Research in Translational Medicine|March 6, 2024
In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamideEmine Begum Gencer, Hasan Yalim Akin, Selami Kocak Toprak, et al.
Pageof 19